| Literature DB >> 33962690 |
Chloe Matthews1,2, Paul D Cotter3,4, Jim O' Mahony1.
Abstract
Mycobacterium avium subsp. paratuberculosis is the causative agent of Johne's disease in ruminants. As an infectious disease that causes reduced milk yields, effects fertility and, eventually, the loss of the animal, it is a huge financial burden for associated industries. Efforts to control MAP infection and Johne's disease are complicated due to difficulties of diagnosis in the early stages of infection and challenges relating to the specificity and sensitivity of current testing methods. The methods that are available contribute to widely used test and cull strategies, vaccination programmes also in place in some countries. Next generation sequencing technologies have opened up new avenues for the discovery of novel biomarkers for disease prediction within MAP genomes and within ruminant microbiomes. Controlling Johne's disease in herds can lead to improved animal health and welfare, in turn leading to increased productivity. With current climate change bills, such as the European Green Deal, targeting livestock production systems for more sustainable practices, managing animal health is now more important than ever before. This review provides an overview of the current knowledge on genomics and detection of MAP as it pertains to Johne's disease.Entities:
Year: 2021 PMID: 33962690 PMCID: PMC8105914 DOI: 10.1186/s42523-021-00089-1
Source DB: PubMed Journal: Anim Microbiome ISSN: 2524-4671
Fig. 1Nomenclature of Mycobacterium avium subsp. paratuberculosis (Adapted from [64]). There are two major groups of strains; Sheep-type, or Type S, and Cattle Type, or Type C, and an “intermediate” Type III, a sub-type of Type S. Type B is a subtype of Type C and is typically isolated from Bison
Primer pairs, targets and conditions commonly used for MAP detection
| Primer pair | Target | Size of product (bp) | PCR conditions | References |
|---|---|---|---|---|
| J5A (Forward 5′-ATGTGGTTGCTGTGTTGGATGG-3′) J5B (Reverse 5′-CCGCCGCAATCAACTCCAG-3′) | IS900 | 298 | 94 °C for 5 min; [94 °C for 30 s, 66 °C for 30 s, and 72 °C for 1 min] × 4 cycles; [94 °C for 30 s, 64 °C for 30 s, and 72 °C for 1 min] × 4 cycles; [94 °C for 30 s, 62 °C for 30 s, and 72 °C for 1 min] × 4 cycles, [94 °C for 30 s, 58 °C for 30 s, and 72 °C for 1 min] × 24 cycles, and a final extension at 72 °C for 7 min | [ |
| IS900qPCRF(Forward 5′-GATGGCCGAAGGAGATTG-3′) IS900qPCRR(Reverse 5′- CACAACCACCTCCGTAACC-3′) | IS900 | 145 | 37 °C for 10 min, followed by initial denaturation at 95 °C for 15 min and 47 cycles of 95 °C for 5 s and 60 °C for 40 s | [ |
| F57qPCRF (Forward 5′-GCCCATTTCATCGATACCC-3′) F57qPCRR (Reverse 5′-GTACCGAATGTTGTTGTCAC-3′) | F57 | 147 | 37 °C for 10 min, followed by initial denaturation at 95 °C for 15 min and 47 cycles of 95 °C for 5 s and 60 °C for 40 s | [ |
| (Forward 5′ -CCGCTAATTGAGAGATGCGATTGG-3') (Reverse 5′ -AATCAACTCCAGCAGCGCGGCCTCG-3′) | IS900 | 229 | 1 cycle at 94 °C for 5 min and 20 cycles at 94 °C for 45 s, 58 °C for 1 min, and 72 °C for 2 min, followed by a final extension cycle at 72 °C for 7 min | [ |
| f57_F (Forward 5′-TTG GAC GAT CCG AAT ATG T-3′) f57_R (Reverse 5′-AGT GGG AGG CGT ACC A-3′) | F57 | 254 | 1 cycle of pre-incubation: 95 °C for 10 min. Followed by 40 cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 20 s | [ |
| mbtA_F3 (Forward 5′–CTC CCG CAA CTC GGT CAC–3) MAP2179_R3 (Reverse 5′–CAC AGC CAG GTG TGA AAG–3′) | mbtA | 307 | 1 cycle of pre-incubation: 95 °C for 10 min. Followed by 40 cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 20 s | [ |
| P90 (Forward 5′-GAA GGG TGT TCG GGG CCG TCG GCC TTA GG- 3′) P91 (Reverse 5′-GGC GTT GAG GTC GAT CGC CCA CGT GAC-3') | IS900 | 394 | 4 min of initial denaturation at 95 °C, 37 cycles of 95 °C for 30 s, 59.5 °C for 30 s and 72 °C for 30 s, followed by a final elongation at 72 °C for 4 min | [ |
| AV1 (Forward 5'-ATGTGGTTGCTGTGTTGGATGG-3') AV2 (Reverse 5'-CCGCCGCAATCAACTCCAG-3') | IS900 | N/A | 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 58 °C for 1 min and 72 °C for 1 min | [ |
Fig. 2Microbiome project workflow for determining the microbiome associated with JD susceptibility or resistance (Adapted from Matthews et al. [160])